Remembering Billy Monti
Your talent, time and treasure aiming at putting this awful disease in the history books is so much appreciated.
The Food and Drug Administration (FDA) announced it has granted approval to MT Pharma America to begin marketing edaravone as a treatment for Amyotrophic Lateral Sclerosis (ALS). The approval of edaravone marks the first new treatment to be approved for ALS in the United States since Rilutek® (Riluzole) was approved in 1995.
Edaravone was developed by Mitsubishi Tanabe Pharma Corporation in Japan, originally as a treatment used in the recovery from stroke. Later, the company worked through several clinical trials in Japan to explore its potential as a treatment for ALS given its properties as a free radical scavenger. Japan’s pharmaceutical regulatory agency approved edaravone to be marketed as a treatment for ALS in 2015. In Japan, edaravone is marketed as Radicut, whereas in the U.S. it will be marketed by MT Pharma America as Radicava following the FDA approval issued today.
For more information, please visit the MT Pharma America website. https://www.mt-pharma-america.com
ALS remains evasive to complete solution so once again we and all stricken families ask you to consider how you can help achieve the mission to eliminate !
The Monti Family
|Remembering Billy Monti||Raised|
|Fran & Bill Monti||$8,316.00|
|John & Dorothy Caralyus||$100.00|
|Peter + Mary Rendich||$0.00|
|Denotes a Team Captain|